PL1637517T3 - Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego - Google Patents
Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowegoInfo
- Publication number
- PL1637517T3 PL1637517T3 PL04746867T PL04746867T PL1637517T3 PL 1637517 T3 PL1637517 T3 PL 1637517T3 PL 04746867 T PL04746867 T PL 04746867T PL 04746867 T PL04746867 T PL 04746867T PL 1637517 T3 PL1637517 T3 PL 1637517T3
- Authority
- PL
- Poland
- Prior art keywords
- hydrogen atom
- hexane
- ester derivative
- dicarboxylic ester
- aminobicyclo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003181930 | 2003-06-26 | ||
| JP2003373511 | 2003-10-31 | ||
| JP2004128663 | 2004-04-23 | ||
| EP04746867A EP1637517B1 (en) | 2003-06-26 | 2004-06-25 | 2-aminobicyclo 3.1.0 hexane-2,6-dicarboxylic ester derivative |
| PCT/JP2004/009398 WO2005000791A1 (ja) | 2003-06-26 | 2004-06-25 | 2-アミノ-ビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸エステル誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1637517T3 true PL1637517T3 (pl) | 2011-04-29 |
Family
ID=33556154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04746867T PL1637517T3 (pl) | 2003-06-26 | 2004-06-25 | Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US7960579B2 (pl) |
| EP (3) | EP2287147B1 (pl) |
| JP (1) | JP4792971B2 (pl) |
| KR (1) | KR101071507B1 (pl) |
| AT (1) | ATE487690T1 (pl) |
| AU (2) | AU2004252017B2 (pl) |
| BR (1) | BRPI0411823A (pl) |
| CA (1) | CA2530706C (pl) |
| CY (1) | CY1110997T1 (pl) |
| DE (1) | DE602004030007D1 (pl) |
| DK (2) | DK1637517T3 (pl) |
| ES (1) | ES2394175T3 (pl) |
| HR (1) | HRP20100619T1 (pl) |
| MX (1) | MXPA05013740A (pl) |
| NO (1) | NO335004B1 (pl) |
| NZ (2) | NZ580554A (pl) |
| PL (1) | PL1637517T3 (pl) |
| PT (1) | PT1637517E (pl) |
| SI (1) | SI1637517T1 (pl) |
| WO (1) | WO2005000791A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1637517T3 (pl) * | 2003-06-26 | 2011-04-29 | Taisho Pharmaceutical Co Ltd | Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego |
| JP5776553B2 (ja) | 2009-11-18 | 2015-09-09 | 大正製薬株式会社 | 酵素を用いた光学活性ビシクロ[3.1.0]ヘキサン誘導体の製造方法 |
| US8642777B2 (en) | 2009-11-19 | 2014-02-04 | Taisho Pharmaceutical Co., Ltd | Process for producing 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative and intermediate thereof |
| KR101554793B1 (ko) * | 2010-11-18 | 2015-09-21 | 일라이 릴리 앤드 캄파니 | mGluR 2/3 길항제로서의 4-치환된-3-벤질옥시-비시클로[3.1.0]헥산 화합물 |
| TWI520935B (zh) | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物 |
| WO2013062680A1 (en) * | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
| AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
| JP5983713B2 (ja) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | 含フッ素アミノ酸のプロドラッグを含有する医薬 |
| FR3026843B1 (fr) * | 2014-10-03 | 2016-11-18 | Univ Pierre Et Marie Curie Paris 6 | Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture |
| CN109071418B (zh) | 2016-04-18 | 2022-03-18 | 大正制药株式会社 | 氨基酸衍生物的前药 |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| KR101877672B1 (ko) | 2017-04-03 | 2018-07-11 | 엘에스산전 주식회사 | Ad컨버터 |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US11501618B1 (en) * | 2018-10-19 | 2022-11-15 | Amazon Technologies, Inc. | Security device with user-configurable motion detection settings |
| CN116444470B (zh) * | 2023-03-29 | 2025-04-04 | 河南中烟工业有限责任公司 | 一种二羧酸二ddmp酯类化合物、制备方法及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| CN1247527C (zh) | 1998-08-31 | 2006-03-29 | 大正制药株式会社 | 6-氟双环[3.1.0]己烷衍生物 |
| JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | 6−フルオロビシクロ[3.1.0]ヘキサン誘導体 |
| CH694053A5 (de) * | 1998-09-03 | 2004-06-30 | Hoffmann La Roche | Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten. |
| US6770676B2 (en) | 2000-06-28 | 2004-08-03 | Taisho Pharmaceutical Co., Ltd. | Dicarboxylic acid derivatives |
| WO2002068380A1 (en) * | 2001-02-22 | 2002-09-06 | Eli Lilly And Company | Synthetic excitatory amino acids |
| PT1459765E (pt) | 2001-12-27 | 2008-10-03 | Taisho Pharmaceutical Co Ltd | Derivados de 6-fluorobiciclo [3.1.0] hexano |
| JP2007063129A (ja) * | 2003-06-26 | 2007-03-15 | Taisho Pharmaceut Co Ltd | 2−アミノ−3−アルコキシビシクロ[3.1.0]ヘキサン誘導体 |
| PL1637517T3 (pl) * | 2003-06-26 | 2011-04-29 | Taisho Pharmaceutical Co Ltd | Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego |
| WO2005000790A1 (ja) | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | 2-アミノビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体 |
-
2004
- 2004-06-25 PL PL04746867T patent/PL1637517T3/pl unknown
- 2004-06-25 NZ NZ580554A patent/NZ580554A/en not_active IP Right Cessation
- 2004-06-25 JP JP2005511127A patent/JP4792971B2/ja not_active Expired - Lifetime
- 2004-06-25 EP EP10181930.8A patent/EP2287147B1/en not_active Expired - Lifetime
- 2004-06-25 PT PT04746867T patent/PT1637517E/pt unknown
- 2004-06-25 MX MXPA05013740A patent/MXPA05013740A/es active IP Right Grant
- 2004-06-25 EP EP09166100A patent/EP2123630B1/en not_active Expired - Lifetime
- 2004-06-25 CA CA2530706A patent/CA2530706C/en not_active Expired - Fee Related
- 2004-06-25 AT AT04746867T patent/ATE487690T1/de active
- 2004-06-25 ES ES09166100T patent/ES2394175T3/es not_active Expired - Lifetime
- 2004-06-25 BR BRPI0411823-5A patent/BRPI0411823A/pt not_active IP Right Cessation
- 2004-06-25 HR HR20100619T patent/HRP20100619T1/hr unknown
- 2004-06-25 DK DK04746867.3T patent/DK1637517T3/da active
- 2004-06-25 KR KR1020057024818A patent/KR101071507B1/ko not_active Expired - Fee Related
- 2004-06-25 DK DK09166100.9T patent/DK2123630T3/da active
- 2004-06-25 WO PCT/JP2004/009398 patent/WO2005000791A1/ja not_active Ceased
- 2004-06-25 SI SI200431569T patent/SI1637517T1/sl unknown
- 2004-06-25 AU AU2004252017A patent/AU2004252017B2/en not_active Ceased
- 2004-06-25 NZ NZ544131A patent/NZ544131A/xx not_active IP Right Cessation
- 2004-06-25 DE DE602004030007T patent/DE602004030007D1/de not_active Expired - Lifetime
- 2004-06-25 EP EP04746867A patent/EP1637517B1/en not_active Expired - Lifetime
- 2004-06-25 US US10/562,018 patent/US7960579B2/en not_active Expired - Fee Related
-
2006
- 2006-01-26 NO NO20060428A patent/NO335004B1/no not_active IP Right Cessation
-
2009
- 2009-07-29 US US12/511,482 patent/US8039647B2/en not_active Expired - Fee Related
- 2009-09-15 AU AU2009217374A patent/AU2009217374B2/en not_active Ceased
-
2010
- 2010-07-30 US US12/847,392 patent/US8076502B2/en not_active Expired - Fee Related
- 2010-12-17 CY CY20101101160T patent/CY1110997T1/el unknown
-
2011
- 2011-09-08 US US13/227,942 patent/US8350060B2/en not_active Expired - Fee Related
- 2011-10-07 US US13/269,242 patent/US8258133B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1637517T1 (sl) | Derivat estra 2-aminobiciklo 3.1.0 heksan-2,6-dikarboksilne kisline | |
| MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| GEP20022676B (en) | 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors | |
| MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
| AU2002239463A1 (en) | Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists | |
| NZ515894A (en) | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | |
| AP1895A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents. | |
| SG155938A1 (en) | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| BRPI0413876A (pt) | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| MXPA05006420A (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal. | |
| MX2008001152A (es) | Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico. | |
| NO20045103L (no) | Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse | |
| TWI265928B (en) | A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw | |
| AP2002002664A0 (en) | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists. | |
| TW200510378A (en) | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | |
| ATE171374T1 (de) | Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln | |
| NZ515407A (en) | 4-Phenyl-pyrimidine derivatives | |
| TW200633984A (en) | Amide compounds and activators of thrombopoietin receptor | |
| WO2003057213A3 (en) | Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor | |
| MXPA05006271A (es) | Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico. | |
| NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
| TW200637552A (en) | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | |
| DE60135016D1 (de) | Indolderivate und deren verwendung in medikamenten | |
| MX2009005676A (es) | Dialquilamino alquil esteres de pivagabina como medicamentos para el tratamiento de alteraciones del sistema nervioso central. |